These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Counting on Fragment Based Drug Design Approach for Drug Discovery. Kashyap A; Singh PK; Silakari O Curr Top Med Chem; 2018; 18(27):2284-2293. PubMed ID: 30499406 [TBL] [Abstract][Full Text] [Related]
24. Advances in distributed computing with modern drug discovery. Banegas-Luna AJ; Imbernón B; Llanes Castro A; Pérez-Garrido A; Cerón-Carrasco JP; Gesing S; Merelli I; D'Agostino D; Pérez-Sánchez H Expert Opin Drug Discov; 2019 Jan; 14(1):9-22. PubMed ID: 30484337 [TBL] [Abstract][Full Text] [Related]
25. Fragment-based drug discovery using NMR spectroscopy. Harner MJ; Frank AO; Fesik SW J Biomol NMR; 2013 Jun; 56(2):65-75. PubMed ID: 23686385 [TBL] [Abstract][Full Text] [Related]
26. Structure simulation with calculated NMR parameters - integrating COSMOS into the CCPN framework. Schneider O; Fogh RH; Sternberg U; Klenin K; Kondov I Stud Health Technol Inform; 2012; 175():162-72. PubMed ID: 22942007 [TBL] [Abstract][Full Text] [Related]
27. Introduction to fragment-based drug discovery. Erlanson DA Top Curr Chem; 2012; 317():1-32. PubMed ID: 21695633 [TBL] [Abstract][Full Text] [Related]
28. MetaboLab--advanced NMR data processing and analysis for metabolomics. Ludwig C; Günther UL BMC Bioinformatics; 2011 Sep; 12():366. PubMed ID: 21914187 [TBL] [Abstract][Full Text] [Related]
29. [Fragment-based drug discovery: concept and aim]. Tanaka D Yakugaku Zasshi; 2010 Mar; 130(3):315-23. PubMed ID: 20190516 [TBL] [Abstract][Full Text] [Related]
30. Lead Identification Through the Synergistic Action of Biomolecular NMR and In Silico Methodologies. Marousis KD; Tsika AC; Birkou M; Matsoukas MT; Spyroulias GA Methods Mol Biol; 2018; 1824():299-316. PubMed ID: 30039415 [TBL] [Abstract][Full Text] [Related]
31. ACFIS: a web server for fragment-based drug discovery. Hao GF; Jiang W; Ye YN; Wu FX; Zhu XL; Guo FB; Yang GF Nucleic Acids Res; 2016 Jul; 44(W1):W550-6. PubMed ID: 27150808 [TBL] [Abstract][Full Text] [Related]
33. A software framework for analysing solid-state MAS NMR data. Stevens TJ; Fogh RH; Boucher W; Higman VA; Eisenmenger F; Bardiaux B; van Rossum BJ; Oschkinat H; Laue ED J Biomol NMR; 2011 Dec; 51(4):437-47. PubMed ID: 21953355 [TBL] [Abstract][Full Text] [Related]
34. Structure-Based Virtual Screening. Li Q; Shah S Methods Mol Biol; 2017; 1558():111-124. PubMed ID: 28150235 [TBL] [Abstract][Full Text] [Related]
35. Development and Validation of 2D Difference Intensity Analysis for Chemical Library Screening by Protein-Detected NMR Spectroscopy. Egner JM; Jensen DR; Olp MD; Kennedy NW; Volkman BF; Peterson FC; Smith BC; Hill RB Chembiochem; 2018 Mar; 19(5):448-458. PubMed ID: 29239081 [TBL] [Abstract][Full Text] [Related]
36. Perspectives on NMR in drug discovery: a technique comes of age. Pellecchia M; Bertini I; Cowburn D; Dalvit C; Giralt E; Jahnke W; James TL; Homans SW; Kessler H; Luchinat C; Meyer B; Oschkinat H; Peng J; Schwalbe H; Siegal G Nat Rev Drug Discov; 2008 Sep; 7(9):738-45. PubMed ID: 19172689 [TBL] [Abstract][Full Text] [Related]
37. Computational Chemistry on a Budget: Supporting Drug Discovery with Limited Resources. Willems H; De Cesco S; Svensson F J Med Chem; 2020 Sep; 63(18):10158-10169. PubMed ID: 32298123 [TBL] [Abstract][Full Text] [Related]
38. NAOMInext - Synthetically feasible fragment growing in a structure-based design context. Sommer K; Flachsenberg F; Rarey M Eur J Med Chem; 2019 Feb; 163():747-762. PubMed ID: 30576905 [TBL] [Abstract][Full Text] [Related]